Cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) in advanced (stage IIIB and stage IV) non-small cell lung cancer (NSCLC). A multicenter phase III study

被引:2
|
作者
Kunitoh, H [1 ]
Saijo, N [1 ]
Nagao, K [1 ]
Ohashi, Y [1 ]
Niitani, H [1 ]
机构
[1] E Japan Lunc Canc CPT 11 Study Grp, Tokyo, Japan
关键词
D O I
10.1016/S0959-8049(99)81409-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
989
引用
收藏
页码:S249 / S250
页数:2
相关论文
共 50 条
  • [1] Final results of phase III study of irinotecan (CPT-11) plus cisplatin (CDDP) versus vindesine (VDS) plus CDDP versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC).
    Fukuoka, M
    Negoro, S
    Masuda, N
    Takada, Y
    Ohashi, Y
    ANNALS OF ONCOLOGY, 2000, 11 : 107 - 107
  • [2] Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) combination in metastatic non-small cell lung cancer (NSCLC)
    Kakolyris, S
    Kouroussis, C
    Souglakos, J
    Androulakis, N
    Mavroudis, D
    Kalbakis, K
    Kotsakis, A
    Sara, E
    Agelaki, S
    Samonis, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 1998, 9 : 96 - 96
  • [3] Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent split-course thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC).
    Nagashima, S
    Fukuda, M
    Kinoshita, A
    Fukuda, M
    Kasai, T
    Takatani, H
    Rikimaru, T
    Soda, H
    Oka, M
    Kohno, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 658S - 658S
  • [4] Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
    Kobayashi, K
    Shinbara, A
    Kamimura, M
    Takeda, Y
    Kudo, K
    Kabe, J
    Hibino, S
    Hino, M
    Shibuya, M
    Kudoh, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (01) : 53 - 58
  • [5] Phase II multi-institutional study of Irinotecan (CPT-11) and Cisplatin (CDDP) on a three-week schedule in patients with advanced non-small cell lung cancer (NSCLC)
    Cardenal, F
    Domine, M
    Massuti, B
    Felip, E
    Carrato, A
    Garrido, P
    Alberola, V
    Antón, A
    Barneto, I
    Rosell, R
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S259 - S259
  • [6] Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
    Kunihiko Kobayashi
    Ayako Shinbara
    Mitsuhiro Kamimura
    Yuichiro Takeda
    Koichiro Kudo
    Junzaburo Kabe
    Suguru Hibino
    Mitsunori Hino
    Masahiko Shibuya
    Shouji Kudoh
    Cancer Chemotherapy and Pharmacology, 1998, 42 : 53 - 58
  • [7] Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC)
    Furuse, K
    Fukuoka, M
    Kuba, M
    Yamori, S
    Nakai, Y
    Negoro, S
    Katagami, N
    Takada, Y
    Kinuwaki, E
    Kawahara, M
    Kubota, K
    Sakuma, A
    Niitani, H
    ANNALS OF ONCOLOGY, 1996, 7 (08) : 815 - 820
  • [8] Cisplatin (CDDP), Paclitaxel (TAX) and Gemcitabine (GEM) as primary chemotherapy for stage IIIA unresectable/IIIB non-small cell lung cancer (NSCLC)
    Mansueto, Giovanni
    Fariello, Anna Maria
    Cianci, Giovanni
    Magnolfi, Emanuela
    Gamucci, Teresa
    ANNALS OF ONCOLOGY, 2005, 16 : 24 - 24
  • [9] Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC).
    Castellano, D., Sr.
    Bartolome, A.
    Font, A.
    Lopez-Martin, A.
    Diz, P.
    Lopez-Brea, M.
    Garrido, P.
    Lianes, P.
    Cortes Funes, H.
    Paz-Ares, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 385S - 385S
  • [10] Phase II study of irinotecan (CPT-11) and cisplatin (CDDp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC)
    Castellano, Daniel
    Bartolome, A.
    Font, A.
    Coronado, Cinthya
    Diz, P.
    Lopez-Brea, M.
    Garrido, P.
    Lianes, P.
    Lopez, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2006, 17 : 229 - 230